Navigation Links
Barrett Katz, MD, MBA, Named CEO of Danube Pharmaceuticals
Date:6/18/2008

ration. Dr. Katz served on the executive committee of the Optic Neuritis Treatment Trial, and has been an active participant and principle investigator of many multi-centre clinical trials.

Dr. Katz currently serves as Clinical Professor of Ophthalmology at New York University School of Medicine as well as at the Weill Medical College of Cornell University. Dr. Katz served as a fellow at Harvard University in Boston, the National Institutes of Health, The National Hospital at Queen's Square in London, and the University of California at San Francisco after completing residencies in Neurology at Harvard Medical School and in Ophthalmology at Tufts-New England Medical Center. He received his MD with honors from the Case Western Reserve University School of Medicine and his AB, magna cum laude, from Colgate University. He is the author of several hundred publications, and the recipient of over two dozen major research grants.

About Danube Pharmaceuticals, Inc.

Danube is a biopharmaceutical company dedicated to the research and development of treatments for diseases of the eye. Danube's lead compound DNB-001, is a small molecule for the treatment of glaucoma available in both oral and topical formulation. In preclinical studies DNB-001 has been shown through novel mechanisms of action to both lower intraocular pressure (IOP) and to provide direct neuroprotective benefits to the optic nerve and its retinal ganglion cells, providing a dual approach to glaucoma therapy not provided by any currently marketed product. DNB-001 has been tested in a Phase I clinical trial in Europe and is currently being studied in a Phase II clinical trial in Europe. For more information on Danube please visit http://www.danubepharma.com .

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from antic
'/>"/>

SOURCE Danube Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. New Study Reports That Ablative Therapy With HALO360 Device Effectively Treats Highest-Risk Category of Barretts Esophagus
2. Ten Latin American Scientists Named 2008 Pew Fellows in the Biomedical Sciences
3. Netsmarts Kevin Scalia Named Chair of the Software and Technology Vendors Association
4. GlaxoSmithKline Named A Top Employer for Promoting Healthy Lifestyles
5. Professors Marc Feldmann and Sir Ravinder Maini Named Winners of the 2008 Dr. Paul Janssen Award for Biomedical Research
6. President and CEO of Velcura Therapeutics Inc. Named the 2008 Grant Thornton Leader and Innovator of the Year
7. Black Box Network Services, ABTECH, Verizon Business and Wyle Named Top Siemens Reseller Partners
8. BioNanomatrix Named Best Management Team at the 2008 Ben Franklin Emerging Business Awards
9. Ash Stevens Inc. Named One of Michigan 50 Companies to Watch
10. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect
11. James W. Backstrom, M.D., Named Chief Medical Officer of Foundation Radiology Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... Synedgen Inc. is pleased to announce ... Manager. , Dr. Nguyen brings to Synedgen critical regulatory ... company as it moves forward in the FDA regulatory ... two years. Dr. Nguyen will lead the management of ... documents that must be completed in order to initiate ...
(Date:5/4/2015)... 4, 2015 Tobira Therapeutics, Inc. (NASDAQ: ... development and commercialization of novel treatments for liver ... its merger with Regado Biosciences, Inc. (NASDAQ: RGDO, ... of the merger, Tobira raised $40 million of ... and all current Tobira institutional investors, including the ...
(Date:5/4/2015)... 2015 GliaCure, a privately-held biotechnology company ... neurological and neuropsychiatric disorders based on glial targets, ... patients in a Phase 1b clinical trial of ... as a potential disease-modifying treatment. GliaCure,s innovative approach ... it both promotes the clearance of amyloid and ...
(Date:5/4/2015)... TORONTO , May 4, 2015 /PRNewswire/ - ... pleased to announce the appointment of Dr. Roger ... extensive experience guiding biotech companies in matters including ... Fluorinov,s leadership team and adds significant regulatory expertise ... Dr. Garceau brings 30 years of pharmaceutical ...
Breaking Biology Technology:Synedgen Announces the Appointment of Regulatory Affairs Manager 2Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 2Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 3Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 4Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 5Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 6GliaCure Initiates Phase 1b Dosing in Alzheimer's Patients 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 3
... Rocky Mountain Biosystems, Inc.(R),(RMBI), a Denver ... a,grant award of approximately $600,000 over two ... Infectious Diseases at the National Institutes of,Health ... technology for influenza vaccination. In the event ...
... Corporation, Joins Board of Directors, Ron ... Myers Appointed Vice President Legal Affairs -, SEATTLE, ... on the development of therapeutics for,autoimmune and inflammatory disorders, ... scientific officer of Dendreon Corporation,(Nasdaq: DNDN ), to ...
... GAITHERSBURG, Md., Feb. 13 Lentigen Corporation ... headquarters and,manufacturing facilities from the University of ... square-foot facility in Gaithersburg., Located along ... accommodate Lentigen,s future growth needs as a ...
Cached Biology Technology:NIH Funds Vaccine Research for Needle-free and Self-Administered Protection Against Pandemic Influenza 2VLST Corporation Announces Board and Executive Management Appointments 2VLST Corporation Announces Board and Executive Management Appointments 3Lentigen to Move Headquarters and Manufacturing to Gaithersburg 2
(Date:4/17/2015)... 2015 Increasing adoption ... advancement to drive biometric systems market in ... According to a recently released TechSci ... ", biometric systems market in Saudi ... at CAGR of over 22% through 2020. The ...
(Date:4/13/2015)... 13, 2015  higi, a leading cloud-based consumer engagement ... fully engage with their communities around health and wellness, ... and secure API.  ... accessible, affordable, and convenient vehicle to receive validated health ... The API will allow higi,s trusted partners, ...
(Date:4/6/2015)... Conn. , Apr. 6, 2015 NXT-ID, ... "Company"), a biometric authentication company focused on the ... has filed provisional patent 62/143028 for ... COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces a ... payments. This patent surrounds the use of miniature ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
... in war zones and farmers tending their fields can have ... In large doses these agents, called organophosphates, are proven, ... chronic disabilities such as problems with learning and memory, headaches ... at the Medical College of Georgia at Georgia Health Sciences ...
... Institute of Standards and Technology (NIST) and the University ... that engineered nanoparticles are able to accumulate within plants ... team led by NIST chemist Bryant C. Nelson showed ... capacity to enter plant root cells and generate many ...
... (self-donated) mononuclear cells derived from bone marrow (BMMNCs) have ... into patients with diabetes who are suffering from critical ... complication of diabetes. The team of researchers in Seville, ... in a recent issue of Cell Transplantation ...
Cached Biology News:Effect of chronic exposure to chemicals used as weapons, pesticides under study 2Effect of chronic exposure to chemicals used as weapons, pesticides under study 3NIST/UMass study finds evidence nanoparticles may increase plant DNA damage 2Autologous bone marrow-derived mononuclear cell transplants can reduce diabetic amputations 2
... of BAC (100+kb), fosmid (40kb), and large ... than any othe BAC vector. On command ... and easy recombinant DNA purification. Available with ... VC) vectors for the highest insert stability. ...
...
... to Sf-900 II SFM.Sf21 ... from Spodoptera frugiperda (Fall ... (1). The Sf21 cells ... suspension culture in Sf-900 ...
6-carboxy-2',4,4',5',7,7'-hexachlorofluorescein, succinimidyl ester (6-HEX, SE) *single isomer*...
Biology Products: